An F.D.A. panel will consider whether Pfizer's vaccine should be authorized for young children.

A key federal advisory committee is set to consider on Tuesday whether to recommend that a pediatric dose of the Pfizer-BioNTech coronavirus vaccine be offered to 5- to 11-year-olds, setting in motion a string of decisions that could lead to children getting shots as early as the end of next week.

Read at Nytimes